Investors focused on the Consumer Discretionary space have likely heard of Caleres (CAL), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of CAL and the rest of the Consumer Discretionary group's stocks.Caleres is one of 261 individual stocks in the Consumer Discretionary sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CAL is currently sporting a Zacks Rank of #1 (Strong Buy).Over the past 90 days, the Zacks Consensus Estimate for CAL's full-year earnings has moved 65% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.According to our latest data, CAL has moved about 43.77% on a year-to-date basis. Meanwhile, the Consumer Discretionary sector has returned an average of -2.50% on a year-to-date basis. As we can see, Caleres is performing better than its sector in the calendar year.Breaking things down more, CAL is a member of the Shoes and Retail Apparel industry, which includes 12 individual companies and currently sits at #24 in the Zacks Industry Rank. On average, this group has gained an average of 15.22% so far this year, meaning that CAL is performing better in terms of year-to-date returns.Going forward, investors interested in Consumer Discretionary stocks should continue to pay close attention to CAL as it looks to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Caleres, Inc. (CAL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research